And have they expanded to other solid cancer within those 12 years??? CF33's preclinical studies has proven it can eliminate over 60 type of solid cancer and there's were the potential commercial valuation is but if it can only treat a few rare solid cancers than the potential market won't be nearly as large and their MC valuation will be determine by the market accordingly and I'm not sure why you keep talking about other clinical trial in the past and how they response to dose escalation as compared to CF33?????
And have they expanded to other solid cancer within those 12...
-
- There are more pages in this discussion • 2,464 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.7¢ |
Change
0.003(5.56%) |
Mkt cap ! $417.2M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.8¢ | 5.2¢ | $2.499M | 45.00M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1921794 | 5.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.7¢ | 1368288 | 7 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IMU (ASX) Chart |